GB2471523A — Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
Assigned to GW Pharma Ltd · Expires 2011-01-05 · 15y expired
What this patent protects
Use of tetrahydrocannabivarin (THCV) either on its own or further comprising cannabidiol (CBD)_in the treatment of epilepsy and more particularly to the treatment of generalized seizures. One embodiment relates to the use of the cannabinoid THCV as a pure or isolated compound, or…
USPTO Abstract
Use of tetrahydrocannabivarin (THCV) either on its own or further comprising cannabidiol (CBD)_in the treatment of epilepsy and more particularly to the treatment of generalized seizures. One embodiment relates to the use of the cannabinoid THCV as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In a further embodiment, the THCV or THCV containing extract is mixed with CBD or a CBD rich extract to benefit from the anti-epileptic activity of the CBD.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.